Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Endo to Buy Par Pharmaceutical for Generic Drug Advantage

May 19, 2015 8:33 am | by Ryan Bushey, Associate Editor | Articles | Comments

Endo spent 8.5 billion on the company for a few key reasons. Read more...


Scientists Announce Major Breakthrough Against Rare Kidney Disease

May 19, 2015 8:32 am | by University of Manchester | News | Comments

Scientists have made a significant breakthrough in the fight against Membranous Nephropathy. Read more...


Drug Oversight

May 19, 2015 8:28 am | by MIT | News | Comments

Researchers have announced a new method that could make it easier to produce drugs such as morphine. Read more...


Inflammation Stops The Biological Clock

May 19, 2015 8:27 am | by Trinity College Dublin | News | Comments

Researchers have uncovered an important link between our body clock and the immune system that will have relevance to the treatment of inflammatory and infectious diseases. Read more...


Microchip Captures Circulating Tumor Clusters, Providing Clue to Cancer’s Spread

May 18, 2015 12:02 pm | by Seth Augenstein, Digital Reporter | News | Comments

A tiny microfluidic chip can capture circulating clusters of tumor cells, researchers said. The find could provide important new clues about how cancer spreads – and could even be a “breakthrough technology,” they said. Read more....


New Life for Old Drug

May 18, 2015 11:54 am | by Rob Levy, Harvard University | News | Comments

Combination drug therapy reduces toxicity and extends survival of patients with metastatic colorectal cancer. Read more...

Eleven Biotherapeutics: Phase 3 Study Results of EBI-005 in Dry Eye Disease

May 18, 2015 11:38 am | News | Comments

Study did not achieve primary endpoints; no statistical difference between EBI-005 and vehicle control. Read more....


AbbVie Receives Orphan Drug Designation for Humira

May 18, 2015 11:27 am | News | Comments

AbbVie announced that the U.S. Food and Drug Administration (FDA) has granted HUMIRA® (adalimumab) orphan drug designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (HS) (Hurley Stage II and Hurley Stage III disease), a painful, chronic inflammatory skin disease. Read more...


Groundbreaking Treatment for Patients with Cystic Fibrosis

May 18, 2015 11:15 am | by Lurie Children's Cystic Fibrosis Center | News | Comments

Treatment with two medications that target the most common genetic cause of cystic fibrosis improves lung function and lowers the rate of pulmonary exacerbations, according to the results from a Phase 3 international clinical trial published online in the New England Journal of Medicine. Read more...


Curing Hepatitis C Could Yield Huge Economic Benefit

May 18, 2015 11:07 am | News | Comments

While a new generation of safer, more effective oral medications to treat hepatitis C patients may cost tens of thousands of dollars for a 12-week regiment, investing in these new therapies could generate savings estimated at more than $3.2 billion annually in the U.S. and five European countries, according to a new study (abstract 228) released at Digestive Disease Week (DDW) 2015. Read more...


Anemia Distorts Regular Method of Diabetes Diagnosis

May 18, 2015 9:23 am | by University of Nottingham | News | Comments

Scientists have found that the blood condition anemia can lead to a false diagnosis of diabetes. Read more...


GSK Study Shows Link Between Improving Health Status and Reduced Mortality in COPD Patients

May 18, 2015 9:13 am | News | Comments

The primary objectives of COPD treatment are to enable patients to effectively manage their disease, improve their health status and slow the rate of decline from this chronic and progressive disease. Read more...


New Tool Will Lead to More Relevant Clinical Trials

May 18, 2015 9:01 am | by University of Abderdeen | News | Comments

A huge number of clinical trials are poorly designed and as such the results they produce can be irrelevant to real end users. Read more...


Astellas Announces New Data from Phase 3 Study for OAB Drug

May 18, 2015 8:53 am | News | Comments

The results of the trial showed that the add-on group achieved its primary efficacy endpoints. Read more...


Lives Could Be Saved with New Hepatitis C Therapy

May 18, 2015 8:37 am | by Monash University | News | Comments

Hepatitis C virus infection is a major public health burden in Australia, with estimates of 230,000 people chronically infected. Read more...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.